As biotech startups sing the blues over 2012 VC deals, others hum a new tune
This article was originally published in Scrip
Venture capital investment in US biotechnology companies ended 2012 on a low note with just $4.1 billion invested in the industry versus the $4.9 billion in 2011. The decline was even more dramatic for startups, since first-time investments in early-stage firms were cut by more than half from $922.3 million to $438.3 million last year.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.